FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1759-1761 June 12, 1997 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Stoute, J. A.

To the Editor: I was surprised that for the study by Stoute et al. (Jan. 9 issue),¹ in which human subjects were intentionally infected with a known disease-producing agent, we are told only that the study was "approved by an institutional review board." Which one? Were the subjects prisoners? Soldiers? Were they from another country, or paid to participate? Having been a member of an institutional review board for many years, I have been involved with studies rejected for far less important ethical reasons.

Doreen B. Brettler, M.D.
Memorial Health Care
Worcester, MA 01605-2982

References

1. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997;336:86-91. [Free Full Text]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.